Clinical Trial Update: Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating amiselimod (MT-1303) for mild to moderate ulcerative colitis has completed. The update does not provide efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Amiselimod (amiselimod)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED